Cargando…

Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial

Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S100B is a biomarker that increases in brain damage. Neuroprotectives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazemian, Kaveh, Ala, Shahram, Mojtahedzadeh, Mojtaba, Abedini, Mahmoud, Alipour, Abbas, Abediankenari, Saeid, Rafati, Mohammadreza, Abaskhanidavanloo, Ali, Mohajerani, Fatemeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462480/
https://www.ncbi.nlm.nih.gov/pubmed/32922474
http://dx.doi.org/10.22037/ijpr.2020.1100952
_version_ 1783576925422223360
author Kazemian, Kaveh
Ala, Shahram
Mojtahedzadeh, Mojtaba
Abedini, Mahmoud
Alipour, Abbas
Abediankenari, Saeid
Rafati, Mohammadreza
Abaskhanidavanloo, Ali
Mohajerani, Fatemeh
author_facet Kazemian, Kaveh
Ala, Shahram
Mojtahedzadeh, Mojtaba
Abedini, Mahmoud
Alipour, Abbas
Abediankenari, Saeid
Rafati, Mohammadreza
Abaskhanidavanloo, Ali
Mohajerani, Fatemeh
author_sort Kazemian, Kaveh
collection PubMed
description Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S100B is a biomarker that increases in brain damage. Neuroprotectives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotective effects of L-carnitine and Fat emulsion (Lipofundin(®)) alone and in combination in patients with ischemic stroke. In a prospective, RCT, and double-blind study 100 patients with MCA ischemic cerebrovascular accident who were admitted in the first 24 h of injury entered the study. The patients were randomly assigned into four groups of L-carnitine, fat emulsion, L-carnitine plus fat emulsion and control. Fat emulsion 10%, 500 mL, was infused over 6 to 12 h and 1 gr of L-carnitine (10 mL of solution) was administered orally to patients in addition to common therapies, according to the American Heart Association and American Stroke Association (AHA/ASA) guidelines. The patients in the control group received only the usual treatment according to stroke guidelines. Blood samples before the intervention, then after 24 h, 48 h, and 7 days later were taken and immunoenzymatic colorimetric method was used for quantitative determination of S100B concentration in the patients’ serum. In the within group analysis, all of our treatment interventions (except control group) have decreased S100B levels statistically significant (P < 0.05). Moreover, changes in observed levels of S100B before and after intervention were different between the groups and the observed differences were statistically significant (P = 0.01). In the GEE model, it was found that S100B levels in the L-carnitine plus fat emulsion group decreased more than the control group and this decline has been statistically significant [P = 0.02, 20.47 (CI 95%: 6.25-34.41)], but in comparison of L-carnitine and fat emulsion group with control group, did not reached statistical significance (P > 0.05). Based on the results obtained from this study, it seems that L-carnitine with fat emulsion could lead to neuroprotective effects with a significant reduction in the S100B biomarker.
format Online
Article
Text
id pubmed-7462480
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-74624802020-09-11 Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial Kazemian, Kaveh Ala, Shahram Mojtahedzadeh, Mojtaba Abedini, Mahmoud Alipour, Abbas Abediankenari, Saeid Rafati, Mohammadreza Abaskhanidavanloo, Ali Mohajerani, Fatemeh Iran J Pharm Res Original Article Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S100B is a biomarker that increases in brain damage. Neuroprotectives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotective effects of L-carnitine and Fat emulsion (Lipofundin(®)) alone and in combination in patients with ischemic stroke. In a prospective, RCT, and double-blind study 100 patients with MCA ischemic cerebrovascular accident who were admitted in the first 24 h of injury entered the study. The patients were randomly assigned into four groups of L-carnitine, fat emulsion, L-carnitine plus fat emulsion and control. Fat emulsion 10%, 500 mL, was infused over 6 to 12 h and 1 gr of L-carnitine (10 mL of solution) was administered orally to patients in addition to common therapies, according to the American Heart Association and American Stroke Association (AHA/ASA) guidelines. The patients in the control group received only the usual treatment according to stroke guidelines. Blood samples before the intervention, then after 24 h, 48 h, and 7 days later were taken and immunoenzymatic colorimetric method was used for quantitative determination of S100B concentration in the patients’ serum. In the within group analysis, all of our treatment interventions (except control group) have decreased S100B levels statistically significant (P < 0.05). Moreover, changes in observed levels of S100B before and after intervention were different between the groups and the observed differences were statistically significant (P = 0.01). In the GEE model, it was found that S100B levels in the L-carnitine plus fat emulsion group decreased more than the control group and this decline has been statistically significant [P = 0.02, 20.47 (CI 95%: 6.25-34.41)], but in comparison of L-carnitine and fat emulsion group with control group, did not reached statistical significance (P > 0.05). Based on the results obtained from this study, it seems that L-carnitine with fat emulsion could lead to neuroprotective effects with a significant reduction in the S100B biomarker. Shaheed Beheshti University of Medical Sciences 2020 /pmc/articles/PMC7462480/ /pubmed/32922474 http://dx.doi.org/10.22037/ijpr.2020.1100952 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Kazemian, Kaveh
Ala, Shahram
Mojtahedzadeh, Mojtaba
Abedini, Mahmoud
Alipour, Abbas
Abediankenari, Saeid
Rafati, Mohammadreza
Abaskhanidavanloo, Ali
Mohajerani, Fatemeh
Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
title Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
title_full Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
title_fullStr Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
title_full_unstemmed Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
title_short Evaluation of Neuroprtective Effects of L-Carnitine and Fat Emulsion in the CVA Patients: A Prospective, Randomized, Double Blind, Clinical Trial
title_sort evaluation of neuroprtective effects of l-carnitine and fat emulsion in the cva patients: a prospective, randomized, double blind, clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7462480/
https://www.ncbi.nlm.nih.gov/pubmed/32922474
http://dx.doi.org/10.22037/ijpr.2020.1100952
work_keys_str_mv AT kazemiankaveh evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT alashahram evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT mojtahedzadehmojtaba evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT abedinimahmoud evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT alipourabbas evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT abediankenarisaeid evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT rafatimohammadreza evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT abaskhanidavanlooali evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial
AT mohajeranifatemeh evaluationofneuroprtectiveeffectsoflcarnitineandfatemulsioninthecvapatientsaprospectiverandomizeddoubleblindclinicaltrial